drugset / Press release
7.5mg Tablets Additionally Approved - Samsca, Vasopressin V2 Receptor Antagonist®
2013-02-08 · Otsuka Pharmaceutical Development & Commercialization, Inc. · original otsuka.co.jp ↗
Tokyo, Japan, February 8, 2013 - Otsuka Pharmaceutical Co., Ltd. today announced that Samsca (tolvaptan), vasopressin V2 receptor antagonist indicated for the treatment of volume overload in patients with heart failure, was granted additional approval of tablets in 7.5mg dosage on February 4, 2013.®
The release as fetched from its publisher. otsuka.co.jp ↗